O2 RegenTech, a an Akron, OH-based medical technology company focused on wound care solutions, raised $600k in funding.
The company has been awarded a $225k National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant to conduct research and development on its oxygenating wound dressing that enhances chronic wound healing, received a $225k National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant and $150k from the Ohio Third Frontier (OTF) Technology Validation and Startup Fund (TVSF).
Led by Dr. Andreas Inmann, President & CEO, O2 RegenTech is advancing OXAID™, a proprietary treatment that provides oxygen, moisture, and protection from bacteria to prevent infections.
The technology is protected by pending patents licensed from The University of Akron in Akron, OH.
FinSMEs
27/01/2017